Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia. - Tabular View

Tracking Information
First Received Date ^ICMJE	May 2, 2002
Last Updated Date	September 2, 2008
Start Date ^ICMJE	January 2001
Primary Completion Date	June 2002 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00035347 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia.
Official Title ^ICMJE
Brief Summary	A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens. After written informed consent is obtained, patients will receive one of the following two treatment regimens: 1) intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous administration of levofloxacin followed by levofloxacin tablets. At least four study visits are normally conducted up to approximately one month after starting therapy. The objective of this study is to compare the safety and efficacy of the two treatment regimens.
Detailed Description
Study Phase	Phase IV
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Condition ^ICMJE	Pneumonia
Intervention ^ICMJE	Drug: IV azithromycin Drug: Ceftriaxone Drug: Azithromycin tablets Drug: IV levofloxacin Drug: Levofloxacin tablets
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	360
Completion Date	June 2002
Primary Completion Date	June 2002 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Patient must be 18 years or older. Patient must be hospitalized and require intravenous therapy for treatment of pneumonia Patient must have pneumonia as documented by relevant signs and symptoms and a positive chest X-ray. Patients cannot have certain underlying diseases or conditions as defined in the study protocol.
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States, Canada, Germany, Greece, Spain

Administrative Information
NCT ID ^ICMJE	NCT00035347
Responsible Party	Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study ID Numbers ^ICMJE	A0661035
Study Sponsor ^ICMJE	Pfizer
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Pfizer
Verification Date	September 2008
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP